New Frontiers in Psoriasis: From Immunogenetics to the Concept of Endotypes

Guest Editor:
Dr. Giovanni Damiani
dr.giovanni.damiani@gmail.com

Deadline for manuscript submissions:
30 April 2020

Message from the Guest Editor

Dear Colleagues,

Psoriasis is now a well-known systemic inflammatory disease that heavily impacts patients' quality of life; however, several efficacious treatments are currently available. Despite the latest therapeutic and biological advances, determining the most suitable drug for a patient (precision medicine) continues to be challenging.

Recently omics, big data, immunogenetics, and artificial intelligence have contributed to making precision medicine possible; in fact, all these technologies have allowed clinicians to better cluster psoriatic patients susceptible to responding to certain drugs or developing complications.

These clusters of clinical, biological, genetic, and therapeutic characteristics depict the endotypes.

This new approach is also of paramount importance in order to decrease healthcare costs related to anti-psoriatic drugs unresponsiveness, lack of response, and complications.

Within this Special Issue of the Journal of Clinical Medicine, we invite you to describe the state-of-the-art for psoriasis care, new therapeutical strategies omics-based, big data, and artificial intelligence contributions in psoriasis precision medicine.

mdpi.com/si/32542